|
|
Volumn 97, Issue 18, 2005, Pages 1327-
|
|
Oh, Canada: Public outcry pushed demand for trastuzumab for early-stage breast cancer
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
NEW DRUG;
TRASTUZUMAB;
ANTINEOPLASTIC AGENT;
MONOCLONAL ANTIBODY;
BREAST CANCER;
BUDGET;
CANADA;
CANCER STAGING;
CANCER SURVIVAL;
DRUG APPROVAL;
DRUG FORMULARY;
DRUG TARGETING;
DRUG USE;
FEMALE;
GOVERNMENT REGULATION;
HEALTH CARE ACCESS;
HEALTH CARE AVAILABILITY;
HEALTH CARE COST;
HEALTH CARE SYSTEM;
HUMAN;
MEDICAL CARE;
MEDICAL SOCIETY;
METASTASIS POTENTIAL;
NOTE;
PRESCRIPTION;
PRIORITY JOURNAL;
RESOURCE ALLOCATION;
ARTICLE;
BREAST TUMOR;
CANCER INVASION;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DISEASE FREE SURVIVAL;
DRUG COST;
ECONOMICS;
MORTALITY;
PATHOLOGY;
PUBLIC OPINION;
RANDOMIZED CONTROLLED TRIAL;
SURVIVAL;
ANTIBODIES, MONOCLONAL;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
CANADA;
DISEASE-FREE SURVIVAL;
DRUG APPROVAL;
DRUG COSTS;
FEMALE;
HUMANS;
NEOPLASM INVASIVENESS;
PUBLIC OPINION;
RANDOMIZED CONTROLLED TRIALS;
SURVIVAL ANALYSIS;
|
|
EID: 25144450628
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/dji327 Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|